SK11952003A3 - Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie - Google Patents

Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie Download PDF

Info

Publication number
SK11952003A3
SK11952003A3 SK1195-2003A SK11952003A SK11952003A3 SK 11952003 A3 SK11952003 A3 SK 11952003A3 SK 11952003 A SK11952003 A SK 11952003A SK 11952003 A3 SK11952003 A3 SK 11952003A3
Authority
SK
Slovakia
Prior art keywords
group
alkyl
substituted
phenyl
compound
Prior art date
Application number
SK1195-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Andrew James Culshaw
Peter Gull
Allan Hallett
Hong-Yong Kim
Max Peter Seiler
Kaspar Zimmermann
Yugang Liu
Mahavir Prashad
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107505A external-priority patent/GB0107505D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK11952003A3 publication Critical patent/SK11952003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1195-2003A 2001-03-26 2002-03-25 Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie SK11952003A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0107505A GB0107505D0 (en) 2001-03-26 2001-03-26 Organic compounds
US33828101P 2001-12-06 2001-12-06
PCT/EP2002/003332 WO2002076946A2 (en) 2001-03-26 2002-03-25 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.

Publications (1)

Publication Number Publication Date
SK11952003A3 true SK11952003A3 (sk) 2004-03-02

Family

ID=26245894

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1195-2003A SK11952003A3 (sk) 2001-03-26 2002-03-25 Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie

Country Status (17)

Country Link
US (1) US7915264B2 (xx)
EP (1) EP1377576A2 (xx)
JP (1) JP4205430B2 (xx)
KR (1) KR20030083755A (xx)
CN (1) CN1500089A (xx)
BR (1) BR0208338A (xx)
CA (1) CA2441599A1 (xx)
CZ (1) CZ20032561A3 (xx)
HU (1) HUP0303623A2 (xx)
IL (1) IL157815A0 (xx)
MX (1) MXPA03008754A (xx)
NO (1) NO326546B1 (xx)
PE (1) PE20021161A1 (xx)
PL (1) PL363907A1 (xx)
RU (1) RU2003130221A (xx)
SK (1) SK11952003A3 (xx)
WO (1) WO2002076946A2 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60133743T2 (de) 2000-08-21 2009-07-02 Pacific Corp. Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
WO2002016319A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same
WO2003062209A2 (en) 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
ES2345044T3 (es) 2002-02-01 2010-09-14 Euro-Celtique S.A. 2-piperazin-piridinas utiles para tratar el dolor.
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
ATE450533T1 (de) 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
EP2281823A3 (en) 2003-05-20 2011-09-07 Ajinomoto Co., Inc. Anti-inflammatory and analgesic piperidine derivatives
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2005049613A1 (en) 2003-11-14 2005-06-02 Merck Sharp & Dohme Limited Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
DE102004039373A1 (de) 2004-08-12 2006-02-23 Grünenthal GmbH Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
GB0506147D0 (en) * 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
GB0509573D0 (en) * 2005-05-11 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
CA2607929A1 (en) * 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
AR056875A1 (es) * 2005-10-19 2007-10-31 Gruenenthal Gmbh Ligandos del receptor vaniloide y su aplicacion para la fabricacion de medicamentos
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
KR100761222B1 (ko) * 2006-03-08 2007-10-04 성균관대학교산학협력단 약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
BRPI0716582A2 (pt) 2006-08-23 2013-10-08 Neurogen Corp Análogos de 2-fenóxi pirimidinona
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008129000A1 (en) * 2007-04-20 2008-10-30 Novartis Ag Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders
CA2692655A1 (en) 2007-07-18 2009-01-22 Novartis Ag Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
NZ595781A (en) * 2008-01-11 2013-07-26 Glenmark Pharmaceuticals Sa Fused pyrimidine derivatives as trpv3 modulators
WO2009121036A2 (en) * 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives
KR101252334B1 (ko) 2008-04-18 2013-04-08 주식회사 대웅제약 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CA2962548A1 (en) 2015-12-23 2017-06-23 Mark York Non-cyclic enamine compounds for absorption of electromagnetic radiation
CN108863949B (zh) * 2018-07-09 2021-01-15 湖南博隽生物医药有限公司 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
IL112235A (en) 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

Also Published As

Publication number Publication date
IL157815A0 (en) 2004-03-28
NO326546B1 (no) 2009-01-05
NO20034122D0 (no) 2003-09-16
PE20021161A1 (es) 2003-02-21
NO20034122L (no) 2003-09-16
MXPA03008754A (es) 2004-02-18
RU2003130221A (ru) 2005-04-10
CA2441599A1 (en) 2002-10-03
EP1377576A2 (en) 2004-01-07
KR20030083755A (ko) 2003-10-30
WO2002076946A2 (en) 2002-10-03
PL363907A1 (en) 2004-11-29
JP4205430B2 (ja) 2009-01-07
WO2002076946A3 (en) 2002-12-27
CN1500089A (zh) 2004-05-26
US7915264B2 (en) 2011-03-29
HUP0303623A2 (hu) 2004-03-01
JP2004528312A (ja) 2004-09-16
US20040138454A1 (en) 2004-07-15
BR0208338A (pt) 2004-03-09
CZ20032561A3 (cs) 2003-12-17

Similar Documents

Publication Publication Date Title
SK11952003A3 (sk) Deriváty pyridínu, spôsoby ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
DE69933573T2 (de) Chinazolinderivate als medikamente
CA2772579C (en) Thioimidazolidinone androgen receptor antagonists and uses thereof
US20080021039A1 (en) Imidazopyridine-derivatives as inducible no-synthase inhibitors
CZ293980B6 (cs) Substituované chinazolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
SK12332003A3 (sk) Tiohydantoíny a ich použitie na liečenie cukrovky
CZ304061B6 (cs) Derivát chinazolinu, farmaceutická kompozice a lécivo s jeho obsahem
SK141097A3 (en) Pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JP2004513125A (ja) 疼痛治療のためのｎ−型カルシウムチャンネル拮抗薬
EP1330444B1 (en) Nitrogenous heterocyclic compounds and process for making them
AU754607B2 (en) Phenanthroline derivatives
CA3030181A1 (en) Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists
ES2354039T3 (es) Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
US20030087931A1 (en) Chemical derivatives and their application as antitelomerease agent
FI80455C (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 8-alkyltio-2-piperazino-pyrimido/5,4-d/pyrimider.
CA3030184A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
AU2017316756A1 (en) Thiohydantoin androgen receptor antagonists for the treatment of cancer
EP3466948B1 (en) Fused pyrimidinopiperidine derivative, and manufacturing method and application thereof
AU2002302469A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
US20040259881A1 (en) Nitrogenous heterocyclic compounds
WO2023046214A1 (zh) 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
BG107219A (bg) Терапевтично приложими нови соли на сск инхибитори, методи за тяхното получаване и фармацевтични състави, които ги съдържат
US20010046991A1 (en) Derivatives of quinoline as alpha-2 antagonists
ZA200306636B (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
JP6595011B2 (ja) 新規ホスホジエステラーゼ５阻害剤とその使用